CPMD
CannaPharmaRX, Inc.0.0040
-0.0005-11.1%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.65MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
Director resigns; exports ramp
CannaPharmaRX director Rick Orman resigned effective January 8, 2026, with no disputes noted. The company shipped 250 kg to Israel in Q4, pricing up on quality, with three more Q1 loads featuring high-THC strains like Black Candyland for Germany. CTO revoked December 12, 2025. Plans call for capital raise to build cultivation rooms.
8-K
CTO revoked amid deficits
CannaPharmaRX's BCSC cease trade order, imposed May 11, 2023, for delinquent 2022 filings, was revoked December 12, 2025, after compliance. Yet working capital sits at a $27M deficit as of September 30, 2025, with $10.8M related-party debt. Company eyes debt restructuring, Cremona expansions, and EU market push. Risks loom large.
10-Q
Q3 FY2025 results
CannaPharmaRx tripled Q3 revenue to $656,606 (up 110% y/y), driven by sales to a German pharmaceutical company, yet posted a $440,000 gross loss from $1,506,292 YTD inventory impairments due to low THC potency and market pricing. Operating loss widened to $936K on royalty expenses, while net loss of $1.5M reflected $506K interest—less than prior year's $632K. Cash dwindled to $927 amid $1.9M operating burn, propped by $1.8M related-party loans; total liabilities hit $34.1M. British Columbia Securities Commission Cease Trade Order blocks equity raises.
8-K
Debt settlement agreements filed
CannaPharmaRX entered letter agreements with payment schedules on August 7, 2025, to settle debts owed to two key debtholders, A. Tal and Koze Investments. This move sidesteps further defaults while preserving cash for operational growth and product delivery. Details were previously noted in the June 30, 2025, 10-Q but omitted from exhibits until now. Agreements secure stability amid funding pressures.
10-Q
Q2 FY2025 results
CannaPharmaRx posted Q2 revenue of $231,608, up from zero a year ago yet still dwarfed by $852,818 in costs, yielding a $621,210 gross loss—worse than 2024's $171,364 hit from impairments alone. Operating loss widened to $840,980 from $517,824, driven by new royalty fees to related party Koze on 192,384 grams sold, while professional fees dropped as operations stabilized. Net loss hit $1,413,458, or $0.00 per share on 662.5 million diluted shares, versus last year's $5.4 million gain from derivative swings; the gap stems mainly from fair-value changes in conversion features and obligations. Cash ticked up to $16,975 on $1.1 million related-party loans, but free cash flow isn't disclosed in the 10-Q, and total debt exceeds $34 million amid defaults on leases and notes. Revenue first trickled in. A British Columbia Cease Trade Order lingers, blocking trades and conversions.
IPO
Employees
Sector
Industry
ACB
Aurora Cannabis Inc.
5.53+0.41
AKAN
Akanda Corp.
0.74+0.02
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.10+0.03
CRLBF
Cresco Labs Inc.
1.75+0.45
CRON
Cronos Group Inc. Common Share
3.16+0.11
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
MRMD
MariMed Inc.
0.12+0.01
NXEN
Nexien BioPharma, Inc.
0.00+0.00
PNXP
Pineapple Express Cannabis Comp
0.01+0.00
YCBD
cbdMD, Inc.
1.43+0.23